3bv9 › Citations

Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo.

Nieman MT, Burke F, Warnock M, Zhou Y, Sweigart J, Chen A, Ricketts D, Lucchesi BR, Chen Z, Di Cera E, Hilfinger J, Kim JS, Mosberg HI, Schmaier AH
J Thromb Haemost 6 837-45 (2008)
Related entries: 1sfq, 1sg8, 1sgi, 1shh

Cited: 12 times
EuropePMC logo PMID: 18315550

Abstract

Background

Novel pentapeptides called Thrombostatin FM compounds consisting mostly of D-isomers and unusual amino acids were prepared based upon the stable angiotensin converting enzyme breakdown product of bradykinin - RPPGF.

Articles - 3bv9 mentioned but not cited (5)

  1. Thrombostatin FM compounds: direct thrombin inhibitors - mechanism of action in vitro and in vivo. Nieman MT, Burke F, Warnock M, Zhou Y, Sweigart J, Chen A, Ricketts D, Lucchesi BR, Chen Z, Di Cera E, Hilfinger J, Kim JS, Mosberg HI, Schmaier AH. J Thromb Haemost 6 837-845 (2008)
  2. Diversity-guided Lamarckian random drift particle swarm optimization for flexible ligand docking. Li C, Sun J, Palade V. BMC Bioinformatics 21 286 (2020)
  3. Divide-and-conquer strategy for large-scale Eulerian solvent excluded surface. Zhao R, Wang M, Tong Y, Wei GW. Commun Inf Syst 18 299-329 (2018)
  4. Assessing How Residual Errors of Scoring Functions Correlate to Ligand Structural Features. Shulga DA, Shaimardanov AR, Ivanov NN, Palyulin VA. Int J Mol Sci 23 15018 (2022)
  5. Structural insights into the activation of blood coagulation factor XI zymogen by thrombin: A computational molecular dynamics study. Shearin S, Venkateswarlu D. Biophys Chem 281 106737 (2022)


Reviews citing this publication (2)

  1. An update on recent patents on thrombin inhibitors (2010 - 2013). Mehta AY, Jin Y, Desai UR. Expert Opin Ther Pat 24 47-67 (2014)
  2. Non-Canonical Amino Acids in Analyses of Protease Structure and Function. Goettig P, Koch NG, Budisa N. Int J Mol Sci 24 14035 (2023)

Articles citing this publication (5)

  1. Tissue factor, blood coagulation, and beyond: an overview. Chu AJ. Int J Inflam 2011 367284 (2011)
  2. Rational design and characterization of D-Phe-Pro-D-Arg-derived direct thrombin inhibitors. Figueiredo AC, Clement CC, Zakia S, Gingold J, Philipp M, Pereira PJ. PLoS One 7 e34354 (2012)
  3. Oral thrombostatin FM19 inhibits prostate cancer. Nieman MT, LaRusch G, Fang C, Zhou Y, Schmaier AH. Thromb Haemost 104 1044-1048 (2010)
  4. Structure-based design of residue 1 analogs of the direct thrombin inhibitor pentapeptide FM 19. Girnys EA, Sobczyk-Kojiro K, Mosberg HI. Chem Biol Drug Des 75 35-39 (2010)
  5. Conformationally restricted analogs of the direct thrombin inhibitor FM 19. Girnys EA, Porter VR, Mosberg HI. Bioorg Med Chem 19 7425-7434 (2011)


Related citations provided by authors (1)

  1. Molecular dissection of Na+ binding to thrombin.. Pineda AO, Carrell CJ, Bush LA, Prasad S, Caccia S, Chen ZW, Mathews FS, Di Cera E J Biol Chem 279 31842-53 (2004)

Quick links